Evidence map›Paper›PMID 41286910›Full record

ReviewJournal of translational medicine2025

Radiology-based artificial intelligence for predicting targeted therapy response in pan-cancer: a comprehensive review.

Bo Yang, Silin Chen, Yunze Wang, Huiran Wang, Jiaqi Deng, Yufei Liu, Jiayi Ran, Yishu Deng, Tailin Li, Xiaohan Zhang and 11 more

Abstract readReview
In one paragraph

Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Bo Yang *Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital, and Centre for Infection Immunity and Cancer (IIC) of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Silin Chen *Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital, and Centre for Infection Immunity and Cancer (IIC) of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Yunze Wang *Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital, and Centre for Infection Immunity and Cancer (IIC) of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Huiran WangDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital, and Centre for Infection Immunity and Cancer (IIC) of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Jiaqi DengDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital, and Centre for Infection Immunity and Cancer (IIC) of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Yufei LiuDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital, and Centre for Infection Immunity and Cancer (IIC) of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Jiayi RanDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital, and Centre for Infection Immunity and Cancer (IIC) of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Yishu DengDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital, and Centre for Infection Immunity and Cancer (IIC) of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Tailin LiDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital, and Centre for Infection Immunity and Cancer (IIC) of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Xiaohan ZhangDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital, and Centre for Infection Immunity and Cancer (IIC) of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Lian WangDepartment of Thoracic Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Xiaochen ZhangDepartment of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Yue WangDepartment of Radiology, The Fourth Affiliated Hospital of School of Medicine, International School of Medicine, Zhejiang University, Yiwu, Zhejiang, 322000, China.
Huaqiong HuangKey Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, China.
David C HayCentre for Regenerative Medicine, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.
Ava KhamsehSchool of Informatics, University of Edinburgh, Edinburgh, EH8 9AB, UK.
Syed Ahmar ShahUsher Institute, University of Edinburgh, Edinburgh, UK.
Canrong LongDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital, and Centre for Infection Immunity and Cancer (IIC) of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Shuifang ChenFirst Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China. chen-sf@zju.edu.cn.
Bing XiaDepartment of Thoracic Cancer, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, Zhejiang, China. xiabing@hospital.westlake.edu.cn.
Jian LiuDepartment of Respiratory and Critical Care Medicine, The Second Affiliated Hospital, and Centre for Infection Immunity and Cancer (IIC) of Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. JianL@intl.zju.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTargeted therapy is central to precision oncology, but identifying patients who will benefit remains challenging. Conventional molecular testing, though the current standard, provides limited predictive value. With recent advances in artificial intelligence (AI) and the widespread availability of imaging data, radiology-based AI models have emerged as valuable non-invasive tools for treatment response assessment.

methodsWe conducted a comprehensive review of 112 studies that developed radiology-based AI models for predicting responses to targeted therapy across various cancer types. The reviewed models were classified into direct prediction approaches, which use end-to-end imaging-based modeling to estimate therapeutic response, and indirect prediction approaches, which infer molecular biomarkers from imaging features to indirectly assess therapeutic sensitivity.

resultsAcross the identified literature, computed tomography (CT) was the most frequently used imaging modality, followed by magnetic resonance imaging (MRI), positron emission tomography (PET), and ultrasound (US). Lung and breast cancers were the most commonly studied diseases, though work has also expanded into gastric, colorectal, liver, kidney, brain, and ovarian cancers. Both machine learning (ML) and deep learning (DL) frameworks have been applied, with ML remaining dominant but DL gaining increasing attention in recent years, likely because ML offers interpretability and suitability for smaller datasets, whereas DL excels in handling complex, high-dimensional data. Collectively, these studies demonstrate promising performance in predicting response to targeted therapy, while also highlighting the diversity of cancer contexts and methodological designs.

conclusionRadiology-based AI offers a non-invasive approach to guide treatment selection and monitoring in targeted therapy. This review summarizes current progress, highlights strengths and limitations of direct and indirect prediction strategies, and discusses future directions. To support accessibility, we also provide a continuously updated interactive website of included resources.

Indexed as

Artificial IntelligenceMolecular Targeted TherapyNeoplasmsRadiologyHumansTreatment OutcomeAIPan-cancerPrognosis and response predictionRadiologyTargeted therapy

Identifiers

PMID41286910
PMCPMC12642378

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.